84C logo

Clene DB:84C Stock Report

Last Price

€0.37

Market Cap

€50.3m

7D

6.3%

1Y

-62.8%

Updated

27 Mar, 2024

Data

Company Financials +

84C Stock Overview

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

84C fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Clene Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clene
Historical stock prices
Current Share PriceUS$0.37
52 Week HighUS$1.10
52 Week LowUS$0.23
Beta0.48
1 Month Change-2.62%
3 Month Change32.86%
1 Year Change-62.80%
3 Year Change-96.82%
5 Year Changen/a
Change since IPO-94.35%

Recent News & Updates

Recent updates

Shareholder Returns

84CDE BiotechsDE Market
7D6.3%2.1%1.9%
1Y-62.8%37.0%7.3%

Return vs Industry: 84C underperformed the German Biotechs industry which returned 37% over the past year.

Return vs Market: 84C underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is 84C's price volatile compared to industry and market?
84C volatility
84C Average Weekly Movement16.8%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 84C's share price has been volatile over the past 3 months.

Volatility Over Time: 84C's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a84Rob Etheringtonhttps://clene.com

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.

Clene Inc. Fundamentals Summary

How do Clene's earnings and revenue compare to its market cap?
84C fundamental statistics
Market cap€50.33m
Earnings (TTM)-€45.75m
Revenue (TTM)€604.36k

83.3x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
84C income statement (TTM)
RevenueUS$654.00k
Cost of RevenueUS$121.00k
Gross ProfitUS$533.00k
Other ExpensesUS$50.04m
Earnings-US$49.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.39
Gross Margin81.50%
Net Profit Margin-7,569.42%
Debt/Equity Ratio199.1%

How did 84C perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.